Friday, 15 Dec 2017

You are here

RheumNow Week in Review - 29 July 2016

Dr Jack Cush reviews this week's highlights from RheumNow.com.

  1. RA: risk of serious infection rises with Interstitial lung dz; 2 fold higher in 1st yr; higher with BOOP & steroids >10mg/day. https://t.co/axzUZhrtHD
  2. FDA warns against using fluoroquinolones (to Rx UTI, bronchitis etc) if other safer Rx options exist. https://t.co/UA0uNmcW3O
  3. Quercetin shown to signif. reduce Uric acid, it inhibits xanthine oxidoreductase in vitro. Not studied in gout. https://t.co/0Fq95UK3PS
  4. CHMP has recommended abatacept for 1st line use (before MTX) in moderate to severe RA. EMA to consider approval https://t.co/kXyD1cXKbO
  5. Anakinra not effective if added to MTX in early RA: CARDERA2 study of 154pts Rx x2yrs. No xray benefit, less DAS/HAQ https://t.co/owvwPhhtss
  6. UK audit of 5000 RA shows only 20% referred from GP to Rheum in 3days (NICE target). Wait time to see Rheum 23-34d https://t.co/5jwIa90EL6
  7. FDA Panel Recommends Brodalumab Approval in Psoriasis
  8. Pravastatin Improves Obstetric Outcomes in Anti-Phospholipid Syndrome Patients. 
  9. Long-Term Safety of Adalimumab Reviewed
  10. MACRA for the Overwhelmed Rheumatologist
  11. The Purse Exam: a Forgotten Part of the Physical. 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.